Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008529 | 0.91 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5005312 | 0.91 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5011989 | 0.87 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5008355 | 0.86 | CDK8 (0.63) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5012012 | 0.85 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5008580 | 0.84 | BRAF (0.47) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5010717 | 0.83 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL27637099 | 0.82 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL5007721 | 0.82 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5008643 | 0.82 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPK14 1938/4885MAPK13 885/4885MAPK12 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.